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MHC-class-II are expressed in a 
subpopulation of human neural 
stem cells in vitro in an IFNγ–
independent fashion and during 
development
B. Vagaska1, S. E. P. New1, C. Alvarez-Gonzalez2,3, F. D’Acquisto4, S. G. Gomez5,  
N. W. Bulstrode6, A. Madrigal2,3 & P. Ferretti1
Expression of major histocompatibility antigens class-2 (MHC-II) under non-inflammatory conditions 
is not usually associated with the nervous system. Comparative analysis of immunogenicity of human 
embryonic/fetal brain-derived neural stem cells (hNSCs) and human mesenchymal stem cells with 
neurogenic potential from umbilical cord (UC-MSCs) and paediatric adipose tissue (ADSCs), while 
highlighting differences in their immunogenicity, led us to discover subsets of neural cells co-expressing 
the neural marker SOX2 and MHC-II antigen in vivo during human CNS development. MHC-II proteins in 
hNSCs are functional, and differently regulated upon differentiation along different lineages. Mimicking 
an inflammatory response using the inflammatory cytokine IFNγ induced MHC-II up-regulation in both 
astrocytes and hNSCs, but not in UC-MSCs and ADSCs, either undifferentiated or differentiated, though 
IFNγ receptor expression was comparable. Together, hypoimmunogenicity of both UC-MSCs and ADSCs 
supports their suitability for allogeneic therapy, while significant immunogenicity of hNSCs and their 
progeny may at least in part underlie negative effects reported in some patients following embryonic 
neural cell grafts. Crucially, we show for the first time that MHC-II expression in developing human 
brains is not restricted to microglia as previously suggested, but is present in discrete subsets of neural 
progenitors and appears to be regulated independently of inflammatory stimuli.
The central nervous system (CNS) has been considered historically to be in an immunologically quiescent state1. 
This “immune privilege state” is due in part to the low expression of key regulators of the immune response, MHC 
class I (MHC-I) and class II (MHC-II) proteins, as well as the limited entry of infiltrating T cells into the CNS1,2. 
However despite this, induction of innate and adaptive immune responses occurs within the CNS following viral 
infection1. Furthermore, recognition of foreign MHC antigens on transplanted cells could be a crucial determi-
nant for the immunological rejection of cell-derived products2,3.
Human neural stem cells (hNSCs) obtained from fetal tissue can successfully differentiate towards all different 
neural cell types4, and fetal cells are still considered the best option for neural cell therapy, as indicated by a recent 
decision of resuming clinical trials using such cells in patients with Parkinson’s disease5. In a human transplant 
paradigm, the fetal cell grafts have to be allogeneic, but the extent of immunoresponse they may elicit is still a 
matter of debate, as it is not possible to carry out these experiments in humans.
Different studies using in vitro models have suggested that allogeneic hNSCs and hNSCs derived from iPS6 or 
ES7 cells do not induce a significant immunoresponse. Odeberg et al. have suggested that although hNSCs express 
MHC, they are not immunogenic8. In contrast, potential hNSC immune response has been reported in other 
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studies9,10. Also results from in vivo animal studies show discrepancy in their conclusions, with immunoresponse 
to neural stem cells reported to be low by some, and significant by others11–13.
The initial hypothesis we set to test was that expression of MHCs in hNSCs was comparable to that of mesen-
chymal stem cells (MSCs), that are considered to have low immunogenicity, though immuno-activation of these 
cells under inflammatory conditions has been suggested14–16, to have immunomodulatory properties, and to have 
the capacity to differentiate along the neural lineage17–19. We focused on mesenchymal cells that could be stably 
maintained and had the potential to be used for neural stem cell therapy, UC-MSCs (umbilical cord-derived 
MSCs) and paediatric ADSCs (adipose tissue-derived stem cells).
The finding that no MHC-II protein expression was observed in UC-MSCs and ADSCs, whereas a significant 
subset of hNSCs were positive, raised the issues of 1) the identity of these cells, as within the normal central nerv-
ous system (CNS) MHC-II are believed to be expressed only by microglia, and 2) their existence in the developing 
human CNS. We show here that the MHC-II-positive cells present in hNSC culture are not microglia as classified 
according to standard microglial markers, nor are simply an artifact of the in vitro system. As shown by analysis 
of MHC-II expression in hNSCs from different embryos, the MHC-II-positive population is constant through 
passages. Crucially, a subset of neural progenitors in the germinal zone, identified by SOX2 labeling, was found 
to co-express MHC-II in the embryonic human CNS. MHC-II in hNSCs are functional in recognizing allogeneic 
T cell receptors, and, unlike ADSCs, are rapidly killed by T cells. MHC-II expression in vitro does not appear to 
be regulated via an autocrine mechanism, and all hNSC cells appear to have the potential to express MHC-II in 
response to IFN-γ stimulation. Finally, we show different regulation of MHC-II in hNSCs induced to differentiate 
along the astrocytic or neurogenic lineages, with down-regulation in the former and up-regulation in the latter. 
Together, our studies suggest the existence of a novel neural stem cell population within the developing human 
CNS constitutively expressing MHC-II, rather than as a consequence of an inflammatory reaction. Furthermore, 
these findings suggest that hNSCs and their progeny may mount an immune response when grafted for thera-
peutic purposes which may have serious implications for the outcome of the procedure and possibly account for 
negative outcome in some patients in clinical trials.
Results
MHC class I and II expression in hNSCs, ADSCs, and UC-MSCs. Potential immunogenicity of hNSCs, 
UC-MSCs and ADSCs was first investigated by comparing expression of the major histocompatibility complexes, 
HLA-A, -B, -C (MHC class I, MHC-I) and HLA-DR, -DP, -DQ (MHC class II, MHC-II), by flow cytometry analy-
sis in 3 independent lines for each cell type. MHC-I was detected in the majority of hNSCs, UC-MSCs and ADSCs 
(Fig. 1A). UC-MSCs and ADSCs were negative for MHC-II on a basal level whilst approximately 50% (average 
from 3 different hNSC lines) of undifferentiated hNSCs expressed MHC-II (Fig. 1A). Immunofluorescence stain-
ing of the 3 hNSC lines confirmed expression of MHC-II and showed that MHC-II-positive cells were also posi-
tive for neural stem cell markers, such as SOX2 (Fig. 1B,C), nestin, PAX6 and Tbr2 (Supplementary Fig. S1A–C). 
The difference in the proportion of MHC-II-positive cells in each line did not appear to change through passages. 
In contrast to hNSCs, human astrocytes were negative for MHC-II (Fig. 1D).
The hNSC lines used here and by others obtained with the same protocol have been thoroughly characterized 
as SOX2-positive neural stem cells4 and we have previously shown by FACS analysis that ≥ 98% of the hNSCs are 
SOX2-positive20. Nonetheless, to rule out that the MHC-II staining observed might be due to microglia contam-
inations, we stained our cultures with microglial markers, such as CD68 and CD11b. hNSCs were completely 
negative for CD11b (Fig. 1E) and CD68 (Supplementary Fig. S1D).
MHC class II expression in the embryonic human nervous system. We then investigated whether 
a population of neural stem cells that expresses MHC-II exist in vivo by immunostaining brain and spinal cord 
sections from human embryos. A small number of MHC-II-positive cells per section (n ≥ 2) was found in all 
sections (n ≥ 6/embryo) stained from 5 different embryos at Carnegie stages 22 (Cs22) and 23 (Cs23); these 
cells were located in the proximity or within the periventricular zone of the spinal cord and brain where the 
SOX2-positive neural progenitors reside (Fig. 2A,B). A subset of MHC-II-positive cells was present also in the 
dorsal root ganglia, within a population defined in other studies as “support cells” (Fig. 2C).
Double-labelling for MHC-II and SOX2 showed that most of the MHC-II-positive cells were also 
SOX2-positive (> 87%), consistent with the co-expression of these proteins observed in vitro (Fig. 2D,E and 
Supplementary Table 1). Co-staining of spinal cord sections with additional neural markers, showed that subsets 
of MHC-II positive cells expressed PAX6 (Fig. 2F) and nestin (Supplementary Fig. S3). At the developmental stage 
examined (Carnegie stage 22), co-expression of MHC-II and Tbr2, that in the mouse is up-regulated during the 
transition from radial glia to intermediate progenitor cells21 and is expressed in hNSCs in vitro (Supplementary 
Fig. S1C), was detected in the dorsal root ganglion but not in the spinal cord (Fig. 2G,H). Whereas cells 
co-expressing MHC-II and neural stem cell markers were consistently detected (≥ 2 double-labelled cells/sec-
tion), no cell double-labelled for MHC-II and the neuroblast marker, doublecortin, was observed (Fig. 2I).
To further investigate the identity of MHC-II-positive-cells in vivo, spinal cord and brain sections were double 
stained for MHC-II and the microglial markers, CD11b (Fig. 3) and CD68 (Supplementary Fig. S4). As exempli-
fied in Fig. 3A,B, cells expressing CD11b were found both in brain and spinal cord in Cs23 embryos, and more 
than 90% of the CD11b-positive cells was also MHC-II positive. Finally, triple staining for MHC-II, CD11b and 
SOX2 in developing spinal cord was carried out at Cs23 (Fig. 3C) and demonstrated the presence of a subset of 
cells positive for all three markers (> 92% of MHC-II-positive cells, Supplementary Table S1). This indicates 
that the human developing nervous system contains a sub-population of SOX2-positive cells that expresses also 
MHC-II and CD11b.
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Figure 1. Detection of MHC proteins by flow cytometry and immunofluorescence staining of MHC class 
II (MHC-II) in combination with the neural stem cell marker, SOX2, and the microglial markers CD11b. 
(A) HLA-A, -B, -C (MHC-class I) and HLA-DR, -DP, -DQ (MHC-class II) assessed by flow cytometry in 
UC-MSCs (FCS), UC-MSCs (CP), ADSCs and hNSCs (light grey curves: negative controls; dark grey curves: 
labelled cells). These are representative histograms of ≥ 3 cell isolates. Data are percentages represented as 
mean ± SEM. Abbreviations: ADSC, adipose-derived stem cells; CP, cord plasma; FCS, fetal calf serum; HLA, 
human leukocyte antigens; NSC, neural stem cells; UCMSC, umbilical cord mesenchymal stem cell. (B) 
MHC-II staining in hNSCs from 3 brains at different stages of development. Cs: Carnegie stage. Nuclei are 
counterstained with Hoechst dye (blue). Note that subsets of hNSCs are positive at all stages. (C) hNSCs (Cs23) 
double-labelled for SOX2 and MHC-II. All nuclei are SOX2-positive, and some cells display also cytoplasmic 
SOX2 staining; a subset of SOX2-positive cells expresses MHC-II protein. (D) hNSCs and astrocytes stained for 
MHC-II; positive cells are observed in hNSCs but not in astrocyte cultures. (E) hNSCs stained for MHC-II and 
CD11b; no CD11b-positive cells are observed.
www.nature.com/scientificreports/
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Functional analysis of MHC-II. In order to establish whether MHC-II proteins expressed by hNSCs are 
functional, we carried out a T cell co-culture assay using allogeneic T cells from a donor of different sex from 
the hNSCs. As shown in Fig. 4A (frames from time-lapse imaging) and in Movies 1–2, T cells rapidly formed 
synapses with the hNSCs. Within a few minutes from adding the T cells, significant morphological changes 
were observed: 30.9% ± 5.3 of hNSCs had started to shrink, as evaluated from images collected at 30 minutes 
of co-culture, and then died (Fig. 4A,B). In contrast, ADSCs did not evoke a T cell response (Movie 3), consist-
ent with their lack of MHC-II expression, and neither morphology nor their survival were affected (Fig. 4C). 
Immunostaining of co-cultured cells for the T cell markers, CD4 and CD8, showed that both CD4 and CD8 
positive T cells interact with hNSCs (Fig. 4D).
We then assessed expression of the IFNγ receptors, IFNγ R1 and IFNγ R2, in hNSCs, UC-MSCs, ADSCs 
and astrocytes by RT-qPCR to establish whether these cells had the potential to respond to IFNγ stimulation. 
As shown in Fig. 5A,B, all cell types expressed both IFNγ receptors. However, the mRNA levels of HLA-DRA 
and CIITA (class II transactivator), the master regulator that modulates both constitutive and IFNγ -induced 
MHC-II expression, were significantly reduced in astrocytes as compared to their parental cell lines (Fig. 5B). 
Having observed that a subset of hNSCs expressed MHC-II proteins, but astrocytes, UC-MSCs and ADSCs did 
Figure 2. Detection of MHC class II and neural markers in human fetal CNS by immunofluorescence.  
(A–C) MHC-II staining in spinal cords (SC) and dorsal root ganglion (DRG) from developing embryos at 
Carnegie stages 22 (Cs22) and 23 (Cs23). Note expression of MHC-II protein in a subset of cells in the germinal 
layer surrounding the central canal. The dorsal root ganglion, indicated by the oval in (C) contains several 
MHC-II-positive cells. The inserts show a group of positive cells at a higher magnification. (D,E) Double-
staining for MHC-II and SOX2 in Cs23 spinal cords (D) and brain (E). MHC-II staining is detected in cells 
expressing SOX2 mainly in the cytoplasm (insert). (F) Spinal cord stained for PAX6 and MHC-II at higher 
magnification. PAX6 protein expression is detected in MHC-II positive cells. (G,H) Double-staining for Tbr2 
and MHC-II protein expression in spinal cord (G) and DRG (H); note the absence of co-labelling in spinal 
cord cells, but co-expression in MHC-II positive cells in DRG. (I) Cs22 spinal cord stained for MHC-II and 
doublecortin (DCX) proteins; no double-labelled cell is detected.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:24251 | DOI: 10.1038/srep24251
not (Fig. 1), we investigated whether MHC-II was up-regulated in the three hNSC lines upon stimulation with 
IFNγ . MHC-II expression in hNSCs was clearly increased by treatment with 10 ng/ml, with virtually all cells 
becoming positive when treated with 200 ng/ml IFNγ (Fig. 5C). Dose-dependent induction of MHC-II by IFNγ 
was observed also in astrocytes; the apparently less intense staining is lilkely due to the flatter morphology of 
astrocytes as compared to hNSCs (Fig. 5D). In contrast, no MHC-II reactivity was observed in either UC-MSCs 
or ADSCs stimulated with IFNγ , nor following their differentiation (Supplementary Table S2, Supplementary 
Fig. S5A–J), independently from the levels of IFNγ receptor expression that were largely comparable to those 
detected in hNSCs (Fig. 5A, Table 1). These results show that whereas hNSCs increased MHC-II expression in 
response to IFNγ , undifferentiated UC-MSCs or ADSCs did not.
We wished to establish whether expression of MHC-II in hNSCs could be due to autocrine effects. Hence 
we first assessed whether these cells expressed IFNγ . As we could not detect any significant amount of IFNγ 
transcript either by RT-PCR or by RT-qPCR, we hypothesised that other components secreted by hNSCs might 
induce MHC-II expression. To this purpose we tested the effect of hNSC conditioned medium on MHC-II 
expression in the MHC-II –negative astrocytes and in hNSCs lines with low levels of MHC-II expression. The 
conditioned medium did not induce MHC-II expression in either of them suggesting that regulation of their 
expression in hNSCs is not via an IFNγ -dependent autocrine mechanisms (Fig. 5E).
Expression of MHC-II following hNSC differentiation. We compared regulation of MHC-II expres-
sion following hNSC differentiation along the astrocytic and neurogenic lineages to establish whether MHC-II 
down-regulation was a general feature of hNSC differentiation. hNSCs induced to undergo astrocytic differen-
tiation were GFAP-positive, as expected for astrocytes, and did not show any MHC-II reactivity (Figs 1C and 
Figure 3. MHC class II (MHC-II), CD11b and SOX2 expression in human fetal CNS detected by 
immunofluorescence. (A,B) Double-staining for MHC-II and CD11b in spinal cord (SC) and brain (Br) from 
embryos at Carnegie stages 23 (Cs23). Note that not all CD11b positive cells are MHC-II positive. (C) Triple 
staining for MHC-II, CD11b and SOX2 in developing spinal cord at Cs23 shows presence of a subset of cells 
positive for all three markers.
www.nature.com/scientificreports/
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Figure 4. Response of hNSCs and ADSCs to T cell detected by time-lapse photography and 
immunofluorescence. (A) Frames taken at different times of co-culture of hNSCs and T cells. (B) Comparison 
of hNSCs and ADSCs response to T cells after 30 minutes in co-culture. (C) MHC-II staining of hNSCs and 
ADSCs co-cultured with T cells. MHC-II reactivity is observed in hNSCs and T cells, but not in ADSCs.  
(D) Expression of CD45, CD4 and CD8 in hNSC and T cell co-cultures; note that all blood-derived cells are 
CD45-positive and that both CD4- and CD8-positive T cells make contact with hNSCs.
www.nature.com/scientificreports/
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6A). Induction of neuronal differentiation of hNSCs resulted in morphological changes and up-regulation of 
MAP2 protein, as well as in an increase in both MHC-II protein and transcript in all lines (Fig. 6B,C). In addition, 
CIITA expression was significantly increased in the differentiated cultures (Fig. 6E). Valproic acid (VPA), one 
Figure 5. Expression of IFNγ receptors (IFNR1 and IFNR2) and effect of IFNγ stimulation on MHC class 
II (MHC-II) expression in undifferentiated hNSCs (cs23) and astrocytes differentiated from the same line. 
(A) Expression of IFNR1 and IFNR2 in hNSCs, ADSCs and UC-MSCs assessed by RT-qPCR. (B) Fold changes 
in the expression of IFNR1 and IFNR2, and HLA-DRA and CIITA in astrocytes in relation to their parental 
hNSCs prior to differentiation assessed by RT-qPCR (Mean ± S.E.M; n = 3, biological replicates); *p < 0.05; 
**p < 0.01 (Student’s t-test). (C) Effect of IFNγ stimulation on hNSCs. Note the dose-dependent increase 
of MHC-II reactivity in hNSCs. (D) Effect of IFNγ stimulation on astrocyte; note MHC-II up-regulation 
upon IFNγ -treatment. (E) Negative control of the MHC-II staining (top panel) and stimulation of astrocytes 
or hNSCs with low MHC-II expression with hNSC conditioned medium (below); no MHC-II induction is 
observed. All scale bars are 100 μm.
www.nature.com/scientificreports/
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of the differentiation medium components, is a histone deacetylase inhibitor, and this class of compounds has 
been shown to regulate CIITA and MHC-II expression22–24. Hence, we assessed whether VPA affected MHC-II 
expression in somatic stem cells; no obvious change was observed either in hNSCs or ADSCs (Supplementary 
Fig. S6). Furthermore, we examined MHC-II reactivity following hNSC neuronal differentiation using a growth 
factor (NGF/BDNF) protocol, in which the culture medium had a completely different composition. MHC-II 
up-regulation was observed also under these experimental conditions (Fig. 6D,E). MHC-II expression increase 
after neuronal differentiation was comparable in the two protocols, both at the protein and RNA level. This sug-
gests that the increase in MHC-II is regulated independently from the composition of the culture medium.
We further assessed MHC-II expression in control and differentiated ADSC and UC-MSCs (Supplementary 
Figs S5–7 and Supplementary Table S2). Neither of these stem cell populations expressed MHC-II, though a few 
positive cells could be detected in sections of fat tissue. Up-regulation of MHC-II in these cells did not occur 
either following neuronal differentiation or differentiation along mesenchymal lineages, and the levels of MHC-II 
and CIITA transcripts in both undifferentiated and neurally differentiated hADSCs were much lower than those 
detected in hNSC (Table 1, Supplementary Fig. S7A,B). Finally, as differentiated UC-MSCs and ADSCs expressed 
both CIITA and IFNγ receptors (Table 1, Supplementary Fig. S7), we assessed whether upon differentiation these 
cells would respond to IFNγ by increasing MHC-II expression. No MHC-II reactivity was detected in the differ-
entiated IFNγ -treated cells by immunocytochemistry (Supplementary Table S2).
Discussion
In this study we provide evidence for a novel population of MHC class II-expressing progenitors that reside in 
the developing human CNS. Our results suggest that these MHC-II molecules are not only functional, but also 
that they are regulated in an IFNγ -independent fashion. Importantly, these findings question the widely accepted 
notion that microglia are the only MHC class-II expressing cells in the central nervous system. To our knowl-
edge this is the first time the existence of a population of MHC-II/SOX2-positve cells in the germinal zone of the 
human embryo has been shown. Furthermore, the potential high immunogenicity of hNSCs is demonstrated in 
parallel with the hypo-immunogenicity of the mesenchymal UC-MSCs and ADSCs. This may have important 
implications for the brain immune response to cell or embryonic neural tissue grafting.
MHC-II reactivity in neural stem cells identify a novel cell population in the developing human 
CNS. Our results show that MHC-II molecules are expressed in neural progenitors both in vitro and in vivo. 
We could not find any evidence based either on morphology or expression of microglial markers in our hNSC 
cultures that would indicate that microglial contamination account for the significant expression of MHC-II we 
observed; in addition, the proportion of MHC-II positive cells did not obviously change with passaging. This sup-
ports the view that MHC-II-positive hNSCs represent a distinct proliferating subpopulation of neural progenitors 
and the findings in vivo are consistent with this hypothesis.
Together our results support the hypothesis of a constitutive rather than autocrine regulation of MHC-II 
expression in hNSCs. IFNγ treatment increased expression in hNSC in a dose-dependent manner, and, impor-
tantly, showed that all hNSCs have the potential of expressing MHC-II. Furthermore, IFNγ mRNA was hardly 
detectable in hNSCs and hNSC-conditioned medium could not elicit an immune response in astrocytes, unlike 
treatment with IFNγ . Finally, MHC-II expression in SOX2-positive cells was consistently found also in the devel-
oping human CNS at stages when the immune system is still poorly developed. Hence, it is most unlikely that 
infective agents had triggered an immune response within the embryonic CNS in all these pregnancies.
An apparent difference in the MHC-II expressing SOX2 positive neural progenitors observed in vivo is their 
co-expression of microglial antigens, CD11 and CD68. These findings open questions about the origin and iden-
tity of these cells in the developing human CNS. Unfortunately, as tracking studies are not feasible in humans, at 
this stage we can only speculate. It is well established that the SOX2-positive hNSCs cells have neuronal and glial 
differentiation potential. The fact that some hNSCs co-express MHC-II and SOX2 suggests a neuroectodermal 
origin of these cells. However, an alternative intriguing possibility is that, as proposed in a study carried out in 
rats, microglia harbour a neuronal and glial differentiation potential that is more readily expressed under culture 
conditions25. Whether such a microglial population really exists in vivo and might be of neuroectodermal rather 
than of mesodermal origin has yet to be seen. Currently we cannot rule out the possibility that old suggestions of 
a dual origin of human microglia based on animal work might have been prematurely dismissed26–28.
Cell type IFNγ R1 IFNγ R2 HLA-II
hNSC-Cs17 3.75 2.90 34.44
hNSC-Cs23 7.63 2.36 11.03
hNSC-10wk 3.87 2.32 9.68
ADSC-h11 4.35 ± 0.65 1.46 ± 0.23
ADSC-h13 5.83 ± 2.91 2.99 ± 1.12 1.70 ± 2.63
UCMSC-3 1.87 ± 1.18 1.68 ± 0.65
UCMSC-4 0.39 ± 0.13 1.17 ± 0.18 0.25 ± 0.11
Table 1.  Fold increase in IFNγ receptor and in HLA-class II transcripts following neuronal 
differentiation of hNSCs (protocol 1) and osteogenic differentiation of ADSC and UCMSC as compared 
to undifferentiated controls assessed by RT-qPCR. Data presented as mean for hNSCs (n = 2, biological 
replicates per cell line), and mean ± S.E.M. for ADSC/UCMSC (n = 3, biological replicates).
www.nature.com/scientificreports/
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We have also shown a great up-regulation in MHC-II upon hNSCs neuronal differentiation. Interestingly, 
recent studies have suggested a role for MHC-I in neurite outgrowth and synaptic plasticity in the developing 
brain, and that dopaminergic neurons in vitro are particularly prone to up-regulate MHC-I in response to inflam-
matory stimuli29–34. It will be important to establish whether MHC-II expression in human neurons in vitro 
reflects transient in vivo developmental events and whether it is restricted to specific neuronal cell types and plays 
specific roles in neural development. For example, given the proposed cross-talk between neurons and microglia 
in the normal brain, transient MHC-II expression in embryonic neurons might play a role in microglia develop-
ment35. Based on the differences in MHC-II expression observed in neurons in vivo and in vitro it is conceivable 
that interactions between neurons with other cell types negatively regulate expression of MHC-II in the devel-
oping and possibly in the adult brain. Hence dys-regulation of these interactions may contribute to disease states 
Figure 6. MHC class II (MHC-II) expression in undifferentiated hNSCs and following neuronal and 
astrocytic differentiation. (A) Detection of MHC-II protein by immunocytochemistry in undifferentiated 
hNSCs and following astrocytic differentiation: differentiated astrocytes are MHC-II-negative and GFAP-
positive. (B) Detection of MHC-II protein by immunocytochemistry in hNSCs from 3 different developing 
brains following neuronal differentiation for 3 weeks. Note the high expression of MHC-II protein in subsets of 
differentiated cells and increased expression upon differentiation. (C) Detection of MHC-II mRNA by RT-qPCR 
(values are means of 2 biological replicates) in the hNSC lines shown in (B); note that the MHC-II transcript 
increases in all lines upon differentiation. (D) Detection of MHC-II proteins by immunocytochemistry 
following differentiation of hNSCs (cs23) for 4 weeks using two different protocols; increased MHC-II 
expression is observed in both conditions. (E) Detection of HLA-DRA and CIITA mRNAs by RT-qPCR in 
hNSCs (cs23) under the differentiation conditions shown in (B). Mean ± S.E.M (n = 3, biological replicates; 
*p < 0.05; **p < 0.001 (one-way ANOVA followed by Tukey t-test).
www.nature.com/scientificreports/
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such as in neurodegenerative diseases. There is some indication that this is the case for MHC-I, whose expression 
renders neurons particularly susceptible to T-cell mediated degeneration34. The scarcity of relevant human tissue 
and the possibility of manipulating it is a limitation to providing rapid answers to these important questions.
MHC-II, but not MHC-I, is differentially expressed in neural and mesenchymal stem cells and 
associated with high immunogenicity. Our comparative analysis of immunogenicity of hNSCs and 
mesenchymal stem cells, paediatric ADSCs and UC-MSCs, highlights important differences among these cell 
lines. In all the cell lines studied most cells express MHC-I. In contrast, only hNSCs, which are rapidly killed 
by T cells, express MHC-II at significant levels. MSCs, either undifferentiated or differentiated, do not express 
MHC-II, nor respond to IFNγ or interact with T cells, consistent with a previous report36. This supports the view 
that MHC-II is the main antigenic complex underlying differences in the immunogenicity of these cells.
The immunogenicity of hNSCs derived from human embryos/fetuses between 41 days and 10 weeks of ges-
tation is more extensive than previously reported and it dramatically increases upon neuronal differentiation. 
The increase in MHC-II expression in hNSCs differentiated towards the neuronal lineage was unexpected. In a 
previous study human neural progenitors grown as neurospheres did not up-regulate MHC-II upon neuronal 
differentiation10. MHC-II up-regulation in our cultures was neuron-specific; it was observed with two completely 
different neuronal differentiation protocols, and did not occur upon differentiation towards the astrocytic lineage, 
when, in contrast, MHC-II was down-regulated. Nonetheless, the astrocytes expressed the IFNγ -receptors, and 
up-regulated MHC-II expression in an IFNγ -dependent pathway, demonstrating the potential for mounting an 
immune response in an inflammatory environment.
Our hNSCs differed from those described by Odeberg et al. and Laguna Goya et al. also in regard to their 
behaviour in co-cultures with T cells8,10. Whereas these authors could co-culture their neural progenitors with 
T cells for several days to assess their ability to induce T cell proliferation, our hNSCs derived from 3 different 
embryos died when exposed to allogeneic T cells, and particularly rapidly when sex-mismatched. In our study 
we used post-adherent T lymphocytes (> 98% pure) rather than the whole population of PBMCs as used in the 
study by Odeberg, or purified CD4+ or CD8+  T-cells as in the Laguna Goya’s study, where 6.5% of neural stem 
cells were MHC-II-positive8,10. It should be noted that the CD4+ and CD8+ T-cells increased their proliferative 
activity when co-cultured with neural stem cells suggesting that an immunogenic response had been triggered. 
Another difference between ours and other studies is in the neural stem/progenitor cells themselves, as we used 
different isolation and growth protocols. In both studies mentioned above, cells were expanded as neurospheres, 
while our hNSCs are grown on laminin as a monolayer, which has been previously reported as the preferable 
method of culture to maintain the phenotype of stem cells stable over time in culture37. It is therefore possible 
that the differences between the studies reflect differences in the populations of neural stem cells isolated and 
expanded in vitro. While expression of MHC-II in neural stem cells in the embryo is likely to play a physiological 
role, it is apparent that they could mount an immune response upon transplantation. Notwithstanding some dif-
ferences in the results between our study and the one by Laguna Goya, there is indeed agreement on the key issue 
that much caution is required in the use of hNSCs and their progeny in cell therapies. MHC-II compatibility and 
use of immunosuppression should be considered to maximize the chances of survival and successful engraftment 
of undifferentiated or differentiated (e.g. dopaminergic neurones) hNSCs.
In contrast to hNSCs, none of the ADSC and UC-MSC lines seem to be immunogenic even when induced 
to express neuronal and glial markers, though less efficiently than hNSCs38. Although it might prove difficult to 
differentiate them into specific mature neuronal sub-types, they can play important trophic and/or immunomod-
ulatory roles in injured CNS39,40. This, together with their low immunogenicity, allowing them to survive longer 
than hNSCs after grafting as reported in animal models41, makes ADSCs and UC-MSCs attractive cell sources for 
aiding repair after traumatic brain injury or hypoxia-ischaemia.
Conclusions
We have identified a previously undiscovered population of MHC-II/SOX2-positive cells in the germinal zone of 
the human embryo that does not appear to be due to an inflammatory response. MHC-II expression in human 
neural progenitors is found both in vitro and in vivo, and also in neurons at least in vitro. This is consistent with 
a non-immune role of MHC-II in the human developing CNS, as it occurs before maturation of the adaptive 
immune system, but might play a role in its development.
Furthermore, the fact that hNSCs can evoke a robust immune response may have important implications for 
the use of embryonic/fetal neural cells therapeutically and perhaps account, at least in part, for unexplained poor 
outcomes noted in some patients during clinical trials utilizing neural cell therapies.
Methods
All chemicals were from Sigma-Aldrich (UK), unless otherwise stated.
All procedures involving human tissue were carried out in accordance to the UK Human Tissue Act 2006.
Human embryonic and fetal tissues. Hindbrains and spinal cords from human embryos between 6–10 weeks 
of gestation from consenting patients were provided by a tissue bank, the Human Developmental Biology Resource 
(HDBR, http://hdbr.org) under ethical approval (NRES Committee London – Fulham, UK). Dissected tissues were 
either dissociated for culturing as described below, or fixed in 4% PFA prior to cryo-embedding and sectioning for 
protein expression analysis by immunofluorescence. Embryos at Carnegie stages 22 (approximately 53 days of gesta-
tion) and 23 (approximately 56 days of gestation) and a fetus at 10 weeks of gestation were used in this study.
Cell growth, differentiation and treatments. All cells were grown at 37 °C with 5% CO2 in a humidified 
incubator.
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Human Neural Stem Cells (hNSCs). hNSCs were isolated as previously described4,42. Cells were grown 
in DMEM/F12 medium with Glutamax (Life Technologies) containing 1% penicillin/streptomycin (Life 
Technologies), 1% N2 supplement, 2% B27 supplement (both Life Technologies), 20 ng/ml human recombinant 
fibroblast growth factor 2 (FGF2), 20 ng/ml human recombinant epidermal growth factor (EGF; both Peprotech), 
50 μg/ml bovine serum albumin (BSA) fraction V and 5 μg/ml heparin, and laminin was added to the medium 
(10 μg/ml) instead of coating the dishes. Most experiments were carried out with cell at passage 10–20, in some 
experiments early (10) and late (30) passages were compared.
Human Pediatric Adipose tissue-Derived Stem Cells (ADSCs). Abdominal adipose tissue was collected from 
consenting patients under ethical approval from the Camden and Islington Community Local Research Ethics 
Committee (London, UK). ADSCs were isolated from lipoaspirates of pediatric patients as previously described17. 
Isolated ADSCs were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) 
containing GlutaMAX™ and supplemented with 10% embryonic stem cell-qualified fetal bovine serum (ES-FBS; 
Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin.
Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs). Whole umbilical cords collected from consenting 
mothers with healthy full-term pregnancies were provided by the Anthony Nolan Cell Therapy Centre under 
ethical approval. Information on the ethical approval held by the Centre, that acts as a research tissue bank, 
can be found at: http://www.anthonynolan.org/about-us/accreditation-and-regulation. UC-MSCs were isolated 
from the Wharton’s jelly of the umbilical cord using a modified protocol described by Weiss et al.43 In brief, the 
cord was rinsed several times with phosphate buffered saline (PBS; PAA Laboratories, Linz, Austria), and the 
blood vessels removed prior to the cord being cut into small pieces (3–5 mm3) and incubated with an enzyme 
solution (composed of 0.5 mg/mL of hyaluronidase and 0.5 mg/mL of collagenase) in a MACS MixTM Tube 
Rotator (Miltenyi Biotec) at 37 °C. After 1 hour, 0.125% trypsin was added to the tissue and it was incubated on 
the tube rotator at 37 °C for an additional 30 minutes. The final product was passed through 70 μm cell strainer 
(BD Bioscience), washed with PBS, and centrifuged. The pellet was treated with ammonium chloride solution 
(STEMCELL Technologies) to lyse any remaining red blood cells. The remaining washed cells were centrifuged 
and resuspended in culture media. Unless stated otherwise, UC-MSCs were cultured in high glucose DMEM 
containing GlutaMAX™ and supplemented with 10% embryonic stem cell-qualified fetal bovine serum and 1% 
penicillin/streptomycin. UC-MSCs were also cultured in human umbilical cord blood low enriched plasma, (CP), 
supplemented with EGF and FGF2; these cells are referred to as UC-MSC (CP) within the text. CP was prepared 
following a protocol modified from Chieregato et al.44. Briefly, CP was thawed at 37 °C to promote cell disruption. 
After thawing, CP was heat-inactivated at 56 °C for 30 minutes, centrifuged at 1000 g for 10 minutes at room tem-
perature, and the CP supernatant stored at − 20 °C until use.
Neural Differentiation. The following neuronal differentiation protocols were used:
Protocol 1. hNSCs were plated in expansion medium on Matrigel coated plates. After 10 days in culture, EGF 
was withdrawn to induce differentiation. After another 7 days in culture the FGF2 and heparin were also with-
drawn from the medium and the cells were maintained in DMEM/F12 medium with Glutamax, supplemented 
with 1% penicillin/streptomycin, 1% N2 supplement, 2% B27 supplement, 50 μg/ml BSA fraction V, 10 ng/ml 
human recombinant nerve growth factor (β NGF) and 10 ng/ml human recombinant brain-derived nerve growth 
factor (BDNF; both Peprotech) for another 7 days to allow maturation.
Protocol 2. hNSCs were plated in expansion media containing laminin and after reaching confluence dif-
ferentiation was induced using DMEM/F12-Glutamax containing 1% penicillin/streptomycin, 10 μM forskolin, 
5 mM KCl, 2 mM valproic acid (VPA), 1 μM hydrocortisone and 5 μg/ml insulin. After 10 days the medium was 
changed to Neurobasal A medium supplemented with 1% L-Glutamine, 1% penicillin/streptomycin and 2% B27 
supplement for another 20 days to allow maturation. Differentiated cells were either collected for analysis of gene 
expression or fixed in 4% paraformaldehyde and characterized by immunocytochemistry as described below.
Protocol 3. A modified “Protocol 2” was used to assess neural differentiation potential of ADSCs and 
UC-MSCs. When cells became confluent the medium was changed to DMEM containing Glutamax, 1% penicil-
lin/streptomycin, 10% ES-FBS, 10 μM forskolin, 5 mM KCl, 2 mM VPA, 1 μm hydrocortisone and 5 μg/ml insulin. 
After 3 week differentiation, cells were analyzed for gene expression. In some experiments, hNSC differentiation 
was induced with this protocol but ES-FBS was omitted to avoid astrocytic differentiation.
Adipogenic Differentiation. Adipogenic differentiation was induced in confluent cells by the addition of a 
medium (DMEM containing Glutamax, 1% penicillin/streptomycin, 10% ES-FBS, 1 μM dexamethasone, 10 ng/ml 
insulin, 500 mM 3-isobutyl-1-methylxanthine and 1 mM rosiglitazone). After 3 weeks, cells were fixed in 4% and 
analyzed semi-quantitatively as previously described17.
Osteogenic Differentiation. Osteogenic differentiation was induced in confluent cells by the addition of a 
medium (DMEM containing Glutamax, 1% penicillin/streptomycin, 10% ES-FBS, 0.1 μM dexamethasone, 
100 μg/ml ascorbate and 10 mM β -glycerophosphate). After 3 weeks, cells were fixed in ice-cold 70% ethanol and 
analyzed semi-quantitatively as previously described17 or analyzed for gene expression.
Chondrogenic Differentiation. Chondrogenic differentiation was induced in confluent cells by the addition of 
DMEM containing Glutamax, 1% penicillin/streptomycin, 10% ES-FBS, 0.1 μM dexamethasone, 50 μg/ml ascor-
bate, 10 ng/ml transforming growth factor β 1 (TGF β 1) and insulin, transferrin and selenium (ITS, Sigma). After 
3 weeks, cells were fixed in 4% PFA and analyzed semi-quantitatively as previously described17 or analyzed for 
gene expression.
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Treatments. Cells were stimulated for 24–48 hours with interferon gamma (IFNγ , Peprotech) at different con-
centrations (10, 50, 200 ng/ml) as indicated in the results. In some experiments cells were exposed to hNSC 
conditioned medium for 48 hours.
Detection of surface antigens by flow cytometry. For cell surface protein analysis, cells were 
pre-incubated in 2.5% FBS in PBS to prevent any non-specific protein binding for 5 minutes, incubated with anti-
bodies (Supplementary Table S2) diluted in 2.5% FBS in PBS at 4 °C for 10 minutes, and then washed twice with 
FACS washing buffer. For negative controls cells were stained using the isotype controls. A BD FACSCalibur TM 
cell analyzer was used to carry out flow cytometry analysis and data were analyzed using FlowJo 6.4.7 software.
Immunofluorescence. All antibodies used are listed in Supplementary Table S3. Cells or tissues were fixed 
in 4% PFA prior to immunocytochemical protein detection. After incubation with a blocking/permeabilizing 
buffer (10% FBS, 3% BSA, and 0.2% Triton-X100 in PBS), cells were incubated with primary antibodies for 
2 hours at room temperature and then for 1 hour with secondary antibodies and Hoechst 33258 (2 μg/ml) at 
room temperature. When double-staining for MHC-II and SOX2, cells were first treated with MHC-II primary 
antibody, then permeabilized and incubated with the SOX2 antibody. Negative controls were incubated with the 
secondary antibody only. For live cell staining, cells were washed in ice-cold PBS, blocked using 2.5% FBS in PBS 
on ice, incubated with the pan-antibody to MHC-II for 15 minutes, extensively washed in PBS, and fixed with 4% 
PFA. Nuclei were counterstained with Hoechst 33258. Images were acquired either using an inverted microscope 
Olympus IX71 equipped ORCA-R2 digital camera (Hamamatsu Corp., Bridgewater, NJ) or by confocal laser 
scanning microscopy (LSM 710, Carl Zeiss, Jena, Germany). Image analysis was performed using Fiji/ImageJ 
software45. Quantification of immunolabeled cells was performed by counting double or triple positive cells in at 
least 5–6 alternate sections per tissue sample from 5 different embryos.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Quantitative Real-Time 
Polymerase Chain Reaction (RT-qPCR). RNA was extracted from cells and tissue using Tri-Reagent (Life 
Technologies) according to the manufacturer’s protocol. RNA was retro-transcribed with Moloney murine leu-
kaemia virus reverse transciptase (Promega). mRNA was quantified by real-time quantitative polymerase chain 
reaction with the 7500 sequence detection system (Applied Biosysytems) and the Quantitect SYBR Green PCR 
kit (Qiagen) following the manufacturer’s instructions. Primers used are listed in Supplementary Table S3. Gene 
expression data were normalized using GAPDH housekeeping gene as a reference.
T cell purification and co-culture. All blood donors gave oral and written consent and cell separation 
from blood samples was covered by ethical approval 05/Q0603/34 (East London and The City Research Ethics 
Committee 1). Blood donors were 20- to 35-year-old healthy men and women who were tested to be negative for 
HIV, hepatitis B virus, and hepatitis C virus. Further exclusion criteria were manifest infections during the last 
4 weeks, fever, symptomatic allergies, abnormal blood cell counts, increased liver enzymes, or medication of any 
kind. Blood from 3 different donors (2 male and 1 female) was used, with one of the male volunteers donating 
blood two times. Hence independent co-culture experiments were repeated 4 times.
Human lymphocytes were isolated using double-gradient density centrifugation as previously described30. The 
fresh venous blood collected was immediately transferred to a tube containing 3.2% sodium citrate (1:10 dilu-
tion). Cells were then separated using the density gradient method: 3 ml of Ficoll Histopaque-10771 was layered 
on top of 3 ml of Ficoll Histopaque-11911 (both from Sigma) to create discrete layers and 6 ml of blood (diluted 
1:1 with RPMI medium) layered on top of the Histopaques. After centrifugation at 400 g at room temperature for 
30 minutes, the peripheral blood mononuclear cells (PBMCs) were aspirated from their appropriate layer using 
a sterile Pasteur pipette and washed with RPMI three times. Cells were resuspended in complete RPMI medium 
and incubated at 37 °C for 2 hours to remove monocyte macrophages. Post-adherent T lymphocytes (> 98% pure) 
were diluted to 1 × 106 cells/ml in standard hNSC medium and incubated for 10 minutes at 37 °C prior to seeding 
over stem cell monolayers. For time-lapse recording, about 5 × 104 hNSCs or 2.5 × 104 ADSCs per well were 
seeded in 12 well tissue culture plates to obtain semi-confluent monolayers. A total of 5 × 105 lymphocytes were 
seeded onto hNSC/ADSCs monolayers and their movement and interaction were recorded using an inverted 
microscope (Zeiss Axiovert) equipped with an incubation chamber with temperature and CO2 percentage con-
trol, and Volocity (Openlab 3.1.5) software. Time-lapse images were taken every 10 seconds for 10 to 30 minutes 
as specified in the movie legends. Movies were generated using Fiji software. At least 5 hNSC/T cell pairs were 
tracked for each experimental condition. Four independent experiments with combinations of 2 donors and 2 cell 
lines were analysed by counting the number of hNSC that had shrunk in the 30 minute co-culture frames and was 
expressed as the percentage of the total number of hNSC present in the field of view.
Statistical Analysis. Data are presented as mean ± SEM. The statistical analysis was performed using 
GraphPad Prism version 5.00 for Windows. Statistical significance was evaluated by Student’s t-test or ANOVA 
followed by a Tukey post-hoc test. A p value equal to or less than 0.05 was considered as statistically significant.
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